GIGA-564

Phase 1Small molecule

GIGA-564 is one of 3 small molecule programs targeting Advanced or Metastatic Solid Tumor Malignancies. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced or Metastatic Solid Tumor MalignanciesRecruiting

Advanced or Metastatic Solid Tumor MalignanciesPhase 1

Recruiting

Competition

Competitive Landscape

6 competitors in Advanced or Metastatic Solid Tumor Malignancies

#DrugCompanyPhaseTrials

Chemotherapy Drug

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

GIGA-564

1 3

Anti-PD-1 Therapy

NNovita Pharmaceuticals, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

Advanced or Metastatic Solid Tumor Malignancies

NCT06258304

Clinical

Trials by Indication[1]

Advanced or Metastatic Solid Tumor Malignancies1 trial

A Dose Escalation and Expansion Study of GIGA-564 in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

Recruiting·GGigaGen, Inc.·Phase 1·NCT06258304·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for GIGA-564. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GIGA-564 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GIGA-564. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GigaGen, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: GGigaGen, Inc.

GIGA-564

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Advanced or Metastatic Solid Tumor Malignancies1 trial

References

Drug Info

Quick Facts

Related News